Skip to main content
All lobbying filings

BIOMARIN PHARMACEUTICAL INC.

Lobbying for BIOMARIN PHARMACEUTICAL INC.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $390,000.00 expenses · posted Apr 21, 2025

Official filing document

 Bills named in this filing 2
  • HR 1262
    Mikaela Naylon Give Kids a Chance Act
  • HR 1509
    Accelerating Kids’ Access to Care Act of 2025
 Lobbying activity 4
Health Issues

HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING

Medicare/Medicaid

HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS

Taxation/Internal Revenue Code

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem